Related Experiment Video
Updated: Feb 25, 2026

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
Published on: July 12, 2024
Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
Jan Trøst Jørgensen1, Karsten Bork Nielsen2, Gitte Kjærsgaard2
1Dx-Rx Institute, Baunevaenget 76, DK-3480 Fredensborg, Denmark.
Abstract:
Background: HER2 serves as an important therapeutic target in gastroesophageal cancer. Differences in HER2 gene signal distribution patterns can be observed at the tissue level, but how it influences the HER2 amplification status has not been studied so far. Here, we investigated the link between HER2 amplification and the different types of gene signal distribution. Methods: Tumor samples from 140 patients with gastroesophageal adenocarcinoma where analyzed using the HER2 IQFISH pharmDx™ assay. Specimens covered non-amplified and amplified cases with a preselected high proportion of HER2 amplified cases. Based on the HER2/CEN-17 ratio, specimens were categorized into amplified or non-amplified. The signal distribution patterns were divided into homogeneous, heterogeneous focal or heterogeneous mosaic. The study was conducted based on anonymized specimens with limited access to clinicopathological data. Results: Among the 140 analyzed specimens 83 had a heterogeneous HER2 signal distribution, with 62 being focal and 21 of the mosaic type. The remaining 57 specimens had a homogeneous signal distribution. HER2 amplification was observed in 63 of the 140 specimens, and nearly all (93.7%) were found among specimens with a heterogeneous focal signal distribution (p<0.0001). The mean HER2/CEN-17 ratio for the focal heterogeneous group was 8.75 (CI95%: 6.87 - 10.63), compared to 1.53 (CI95%: 1.45 - 1.61) and 1.70 (CI95%: 1.22 - 2.18) for the heterogeneous mosaic and homogeneous groups, respectively, (p<0.0001). Conclusions: A clear relationship between HER2 amplification and the focal heterogeneous signal distribution was demonstrated in tumor specimens from patients with gastroesophageal cancer. Furthermore, we raise the hypothesis that the signal distribution patterns observed with FISH might be related to different subpopulations of HER2 positive tumor cells.
Insights
HER2 amplification in gastroesophageal cancer is strongly linked to a focal heterogeneous gene signal distribution. This finding suggests distinct tumor cell subpopulations may influence HER2 status.
Area of Science:
- Oncology
- Genetics
- Molecular Diagnostics
Background:
- HER2 is a key therapeutic target in gastroesophageal cancer.
- HER2 gene signal distribution patterns vary within tissues.
- The influence of these patterns on HER2 amplification status was previously unstudied.
Purpose of the Study:
- To investigate the association between HER2 amplification and different gene signal distribution patterns.
- To analyze HER2/CEN-17 ratios in relation to signal distribution types.
Main Methods:
- Analyzed 140 gastroesophageal adenocarcinoma tumor samples using the HER2 IQFISH pharmDx™ assay.
- Categorized specimens into amplified or non-amplified based on HER2/CEN-17 ratio.
- Classified signal distribution as homogeneous, heterogeneous focal, or heterogeneous mosaic.
Main Results:
- 83 specimens showed heterogeneous HER2 signal distribution (62 focal, 21 mosaic); 57 had homogeneous distribution.
- HER2 amplification occurred in 63 specimens, with 93.7% found in the focal heterogeneous group (p<0.0001).
- Mean HER2/CEN-17 ratio was significantly higher in the focal heterogeneous group (8.75) compared to mosaic (1.53) and homogeneous (1.70) groups (p<0.0001).
Conclusions:
- A significant relationship exists between HER2 amplification and focal heterogeneous signal distribution in gastroesophageal cancer.
- This pattern may indicate the presence of diverse HER2-positive tumor cell subpopulations.
- FISH signal patterns could offer insights into tumor heterogeneity and therapeutic response.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025